Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions

Mihaela Aldea; Arianna Marinello; David Guyon; Anas Gazzah; Fabrice Barlesi; David Planchard; Benjamin Besse

doi:10.1001/jamaoncol.2023.3625

Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions

JAMA Oncol. 2023 Nov 1;9(11):1583-1584. doi: 10.1001/jamaoncol.2023.3625.

Authors

Mihaela Aldea^{1

2}, Arianna Marinello¹, David Guyon³, Anas Gazzah⁴, Fabrice Barlesi^{1

2}, David Planchard¹, Benjamin Besse^{1

2}

Affiliations

¹ Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France.
² Faculty of Medicine, Paris Saclay University, Paris, France.
³ Department of Medical Oncology, Neuro-oncology Unit, Gustave Roussy, Villejuif, France.
⁴ Department of Drug Development Department, CICT, Gustave Roussy, Villejuif, France.

PMID: 37707807
PMCID: PMC10502692 (available on 2024-09-14)
DOI: 10.1001/jamaoncol.2023.3625

No abstract available

Plain language summary

This cohort study examines the incidence, risks, and characteristics of deep vein thrombosis, pulmonary embolism, arterial thrombosis, and stroke among patients with non–small cell lung cancer (NSCLC) and RET fusions.

MeSH terms

Carcinoma, Non-Small-Cell Lung* / complications
Carcinoma, Non-Small-Cell Lung* / epidemiology
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Lung Neoplasms* / epidemiology
Lung Neoplasms* / genetics
Prevalence
Proto-Oncogene Proteins c-ret / genetics
Thromboembolism* / epidemiology

Substances

RET protein, human
Proto-Oncogene Proteins c-ret